MD, PhD. Oncólogo | Unidad de Cáncer de Mama y Ginecológico Hospital 12 de Octubre (Spain) | ESMO Young Oncologists Committee Chair
Joined May 2012
- Tweets2.6K
- Following694
- Followers4.6K
- Likes7.5K
📣Join us today for the YO Brunch session 1: Digital technologies in YO daily life 📱💻
Starting at 10:30, Santander auditorium
Lunch box included!
Proffered paper BC session 2 at #ESMO26:
Great to see EVE + ET as comparator arm in post-CDK4/6i RCT
The ph2 FOURLIGHT-01 trial:
Atirmociclib (selective CDK4i) + fulvestrant shows a clinically meaningful PFS of 9,4 months vs 6,6 (fulve / exe + eve)
#ESMOAmbassadors @myESMO
Rodrigo Sánchez-Bayona retweeted
Thank you to the @myESMO #ESMO26 #YOC for the invitation to you for the #YOMentorshipSession
We discussed #ScienceCommunication and #MedicalJournalism, within many other topics!!!
Ver active and participating group of YOCs! Thank you all 🙏
#ESMOAmbassadors
Rodrigo Sánchez-Bayona retweeted
#ESMO26: Final results from the TALENT #ClinicalTrial show low pathological complete response rates with the antibody–drug conjugate (#ADC) trastuzumab deruxtecan in HR-positive, HER2-low #EarlyBreastCancer, as discussed by @breastDoktor #InsightsbyESMO
➡️ ow.ly/ZBwi50ZZXLm
📣 Presented today at #ESMO26 with concomitant publication at @ESMO_Open
Results from the PROCURE Project, assessing genetic predisposition to ILD in patients treated with TDXd
🧬 New study from the PROCURE project in @ESMO_Open @myESMO explores the genetic basis of TDxD–induced ILD in breast cancer.
📊 290 patients
• ILD incidence: 11.4%
• Strongest association mapped near HLA-F
• Additional signals SLCO1B1, CYP3A4
kwnsfk27.r.eu-west-1.awstrac…
At 15y analyses, extended ET did not show an OS benefit. Now both adjuvant abema and ribo have positive OS results. Do you think there is still a role for extending ET after adjuvant CDK4/6i?
#ESMO26 #ESMOAmbassadors @myESMO
61%Yes
39%No
51 votes • 1 daysNow at #ESMO26 new phase 3 evidence for novel antiHER2 ADCs in HER2low MBC.
The question is: is chemotherapy still a valid comparator in this setting where TDXd has become a new standard?
#ESMOAmbassadors @myESMO
Rodrigo Sánchez-Bayona retweeted
Attending #ESMO26? 📱Download the ESMO Events App to browse the programme, save your must-attend sessions and create your personalised agenda before you arrive.
A simple step to help you make the most of your congress experience from day one.
🔗 ow.ly/nbMX50ZZXgz
Rodrigo Sánchez-Bayona retweeted
New at #ESMO26: the ESMO Principles for Humanising Scientific Reporting.
Designed to strengthen the communication of oncology research while maintaining scientific rigour and patient relevance.
🔗 ow.ly/WzeJ50ZZIqH
Rodrigo Sánchez-Bayona retweeted
📰 @ESMO_Open publica el paper 'Germline pharmacogenetic variants associated with trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer: PROCURE project', un estudio multicéntrico presentado por el Dr. @Rodrosb en la Plenaria de #SEOM26
🔗 sciencedirect.com/science/ar…
🧬 New study from the PROCURE project in @ESMO_Open @myESMO explores the genetic basis of TDxD–induced ILD in breast cancer.
📊 290 patients
• ILD incidence: 11.4%
• Strongest association mapped near HLA-F
• Additional signals SLCO1B1, CYP3A4
kwnsfk27.r.eu-west-1.awstrac…
Rodrigo Sánchez-Bayona retweeted
📌 2nd International Multidisciplinary Consensus on the Integration of Radiation Therapy with New Systemic Treatments @ESTRO_RT
🧬PARPi and Immunotherapy in Breast
Cancer: Clinical Evidence, Patient Selection and Therapeutic Indications
@Rodrosb 🇪🇸
#FlorenceConsensus26 @OncoAlert #OncoAlertAF
Rodrigo Sánchez-Bayona retweeted
Superb @Rodrosb brings the systemic therapy perspective.
PARP inhibitors and immunotherapy in #BreastCancer: which patients, which indications, and how strong is the evidence? Key discussion on combining these agents with RT!
@OncoAlert @KaidarOrit
Rodrigo Sánchez-Bayona retweeted
Orit Kaidar Person and Rodrigo Sanchez Bayona dance showing radiobiological rationale and clinical evidence for combination of PARPi and ICIs with #radiotherapy in #BreastCancer
#FlorenceConsensus26 #OncoAlert @OncoAlert @ESTRO_RT @myESMO
Rodrigo Sánchez-Bayona retweeted
🔴 Plenaria #SEOM26
📰 Identifican genes relacionados con el riesgo de neumonitis por trastuzumab-deruxtecán en pacientes con cáncer de mama
🩺 Dr. @Rodrosb, secretario científico de @_SEOM y oncólogo médico del @H12Octubre
seom.org/images/NP_Plenaria_…
Rodrigo Sánchez-Bayona retweeted
Outcomes of elacestrant in pts with ER+ HER2, ESR1m metastatic breast cancer who received prior ET & CDK4/6 inhibitor in a RW setting in @ESMO_Open.Durable benefit of elacestrant with 8.2 months of mTTNT after 1 to 2 lines of ET+CDK4/6i. esmoopen.com/article/S2059-7…
Rodrigo Sánchez-Bayona retweeted
Managing HR+/HER2- Early Breast Cancer in the Genomic Era - Rodrigo Sanchez Bayona (@Rodrosb)
oncodaily.com/science/rodrig…
Rodrigo Sánchez-Bayona retweeted
We would like to inform you that your post has been published on OncoDaily. Thank you for sharing.
oncodaily.com/science/rodrig…
